Abstracts must be submitted online. Complete instructions can be found in the submission portal. The deadline to submit an abstract is Thursday, October 1, 2026 at 11:59pm Eastern Standard Time (EST). No exceptions will be made.

Submission length is limited to 2,500 characters.

Characters in the abstract title, body, and table/image caption will be counted (including spaces). Characters in the author and institution listing will not be counted. There is a strict limit of one graph, figure, or table to each submitted abstract. No exceptions will be made

Abstracts which have been published online or in print in a journal at the time of submission are NOT eligible for submission.

One-year clinical follow-up is required for abstract submission. The one-year follow-up rule does not apply to categories of basic science or biomechanical studies or for topics where one-year follow-up is irrelevant, such as 30-day re-admission rates.

Utilizing guidance from the Accrediting Council of Continuing Education (ACCME) regarding responsible use of Artificial Intelligence (AI), SRS requires that you disclose whether AI tools have been used to generate, analyze, or edit your abstract and/or its associated materials, such as uploaded images, figures, or charts. Routine spelling or grammar tools do not require disclosure.

If AI was used, the authors of the abstract remain fully accountable for the submitted content and must attest that all AI-assisted content has been human-verified for clinical accuracy, evidence-based integrity, and the absence of commercial bias.

The Scoliosis Research Society (SRS) must ensure balance, independence, objectivity, and scientific rigor in all educational activities. Therefore, as a person who is in position to influence or control the content of a CME activity, ALL abstract authors must disclose all financial relationships healfd in the past 24 months with ineligible companies.* If the financial relationship has occurred in teh past 24 month, but has since ended, we still require you to disclose the relationship. Visit the following link to disclose: https://imast.owpm2.com/author

*An ineligible company is an entity whose primary business is producing, marketing, selling, reselling, or distributing health care goods or services consumed by or on patients. For specific examples of ineligible companies, visit accme.org/standards.

SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, ROTEM, , XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any relevant financial relationships. When there is a known relevant financial relationship, expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.

Please view the SRS Product Translation Glossary for more information.

All abstracts submitted will be reviewed and graded, in blinded fashion, by the IMAST Committee. One-year follow-up is required for paper submitted to IMAST. Based upon abstract grading, those selected will be assigned to a four-minute oral presentation or a three-minute E-Point presentation. Acceptance notification will be sent in December 2026.

By submitting an abstract to IMAST, abstract authors agree that at least one (1) author will attend the meeting for which the abstract is accepted and will be available to present on the date and at the time assigned by the organizing committees. AUthors will be notified of presentation times at the time of or shortly after notification of acceptance and are expected to make appropriate travel arrangements to ensure that at least one of the abstract's author will be in attendance. In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth may be withdrawn from the program.